Core Viewpoint - Sanyuan Biotech is facing multiple dynamics including the final ruling of anti-dumping duties in the U.S., progress on the allulose project, and the promotion of new products [1] Group 1: Stock Recent Trends - The U.S. Department of Commerce has announced a final ruling on anti-dumping and countervailing investigations regarding Chinese erythritol products, with Sanyuan Biotech facing a comprehensive execution tax rate of 93.58% for exports to the U.S. This ruling will take effect upon publication in the Federal Register and may have a lasting impact on the company's U.S. market operations [2] - The European Union will impose a 156.7% anti-dumping tax on Chinese erythritol starting January 2025, lasting for five years. The company has responded by launching blended products, indicating that the impact of this event may persist [2] Group 2: Company Project Progress - The company's annual production project for 20,000 tons of allulose has completed the construction of the main engineering and equipment installation for the remaining 10,000 tons of capacity. The next steps will involve organizing environmental assessments and gradually advancing production. This project aims to enrich the product portfolio, but the production schedule and benefits are subject to approval processes and market demand [3] Group 3: Business Development Status - Sanyuan Biotech is continuously providing samples of Reb M to domestic and international potential customers and conducting application experiments. Some customers have already incorporated it into their reduced-sugar product formulations. Tagatose, as a key new functional sugar, is in a critical phase of market promotion and industrial application [4] Group 4: Company Status - The company will hold a board meeting on February 4, 2026, to review the proposal for convening the first extraordinary shareholders' meeting of 2026, with further arrangements to be announced [5]

Group 1 - The company is actively providing samples of Reb M to domestic and international potential clients, with some clients already incorporating it into their sugar-reduction product formulations [2] - Tagatose, as a key focus for the company, is currently in a critical phase of market promotion and industrial application, with steady progress being made [2] - The company has utilized Reb M in the formulation of products containing erythritol and allulose, enhancing product quality and market competitiveness [2]

Core Viewpoint - The trade friction between China and the U.S. regarding erythritol has reached a critical point, with significant tariffs imposed on Chinese products, impacting market access and prompting companies to diversify their strategies to mitigate risks [2][3][4]. Group 1: Tariff Implications - The U.S. Department of Commerce announced final anti-dumping and countervailing duties on Chinese erythritol products, with a countervailing duty of 8.63% and an anti-dumping duty of 84.95%, resulting in a combined tariff of 93.58% [2][3]. - This combined tariff, although reduced from a previous rate of 450.64%, still poses a significant barrier for Chinese companies seeking to enter the U.S. market [2][3][4]. Group 2: Market Dynamics - The initial investigation began in December 2024, initiated by U.S. producer Cargill, leading to a significant drop in Chinese erythritol exports to the U.S. due to high tariffs [3]. - The competitive landscape in the sugar substitute industry remains challenging, with nearly 94% tariffs creating a heavy burden for companies relying solely on raw material exports [4]. Group 3: Strategic Responses - In response to the tariffs, the company is accelerating the production of allulose, a promising new product, with plans for a 20,000-ton annual production capacity, which is expected to meet growing demand in the U.S. and other markets [7][8]. - The company is also diversifying its product offerings by developing high-value products such as rebaudioside M and sweet tea glycosides, as well as cosmetic raw materials, to reduce reliance on erythritol [8]. - To counteract the challenges in the U.S. market, the company is expanding into neighboring markets like Canada and Mexico, and is also addressing raw material cost issues by building a corn processing line [8].

此次美国商务部公布的为反倾销、反补贴调查终裁结果，美国国际贸易委员会（ITC）预计将于2026年 3月公布产业损害最终裁定。若ITC做出肯定性裁定，美国商务部将正式发布反倾销、反补贴税令。本 次"双反"调查对公司在美市场的业务拓展产生了实质性压力。鉴于公司通过前述特定渠道（SRA）出口 美国的综合执行税率（反倾销现金保证金率84.95%+反补贴税率8.63%）仍达到93.58%，该税率水平预 计将削弱公司相关产品在美市场的成本竞争优势，公司面临涉案产品订单缩减及市场份额流失的风险。 目前，公司正在采取多种措施积极应对。首先，在严守贸易合规的前提下，公司将加强与具备特定单独 税率资格的贸易渠道（SRA）合作，充分利用相对较低的综合税率通道维持美国市场的业务连续性。同 时，公司将充分利用前述产品排除条款，加大对美出口非涉案的小包装复配糖产品，并积极推广莱鲍迪 苷M、阿洛酮糖及塔格糖等非涉案新产品，通过差异化布局提升出口业务的抗风险能力。 2026年2月4日，美国商务部公布了关于本次赤藓糖醇反倾销调查终裁结果。公司作为出口商未能获得分 别税率资格，直接向美国出口时适用184.26%的中国全国统一税率，较初裁（450 ...

Core Viewpoint - The U.S. Department of Commerce has issued final rulings on anti-dumping and countervailing duties for erythritol products from China, significantly impacting the company's market operations in the U.S. [1][2] Group 1: Final Rulings - The final countervailing duty rate for the company is set at 8.63%, while other Chinese producers/exporters face rates between 4.54% and 8.12% [1] - The final anti-dumping duty for the company is 184.26%, a reduction of 266.38% from the preliminary rate of 450.64% [1] - The company can export through a specific separate rate channel (SRA) with an anti-dumping cash deposit rate of 84.95%, while other qualified producers/exporters have rates between 84.86% and 84.95% [1] Group 2: Market Impact and Response - The dual investigation ("double reverse") poses substantial pressure on the company's business expansion in the U.S. market [2] - The combined effective tax rate for exports through the SRA channel is 93.58%, which is expected to weaken the company's cost competitiveness in the U.S. market [2] - The company is taking measures to mitigate risks, including strengthening cooperation with trade channels that have specific separate rate qualifications and promoting non-involved new products to enhance export resilience [2]

Core Viewpoint - Sanwei Biotech is actively advancing the industrialization and market expansion of diversified products, including allulose, tagatose, mannitol, and others, to enhance its product structure and overall business resilience [2]. Product Development - Allulose: The company has launched a production capacity of 10,000 tons, with an additional 10,000 tons under construction. Sales from January to September have shown significant year-on-year growth, meeting the needs of domestic clients like Nayuki Tea and steadily increasing overseas demand [2]. - Tagatose: Approved as a new food ingredient in China since 2014 and recognized in multiple countries, the company is optimizing production processes to reduce costs and enhance market potential. Tagatose and allulose both possess health benefits related to blood sugar control and gut microbiota regulation, with ongoing efficacy research in collaboration with Binzhou Medical University [2]. - Mannose: The company has small-scale production capabilities and is in the process of applying for domestic and overseas certifications. Mannose is gaining attention for its applications in medical research and health nutrition [2]. - Mannitol: The company has developed a cost advantage through new production processes and plans to gradually introduce it to the market [2]. - Reb M: The market acceptance of Reb M is increasing through continuous promotion, and the company has also developed sweet tea glycosides from regular steviol glycosides, with mature processing technology [2]. - Cosmetic Ingredients: The company leverages its synthetic biology technology to develop glycerol glycosides, ascorbic acid glucosides, and alpha arbutin, expanding its product applications in the daily chemical sector [2]. Strategic Goals - The gradual advancement of these products will help the company maintain its core competitiveness in erythritol while enhancing product diversity and improving overall business stability and risk resistance [2].